On June 19-21, Evolink took part in the annual exhibition "MVC: Grain, Animal Feed, Veterinary Medicine" in Moscow. During the awarding ceremony of the winners of the competition "Innovations in the production of medicines for veterinary use", the company was awarded a diploma of the II degree for a drug based on Eshrifag bacteriophages. A remedy for coli-salmonella infections in pigs and birds became one of the winners of the nomination "Immunobiological medicinal products for veterinary use used in pig breeding".
Bacteriophages do not affect the beneficial microflora of the body, acting purposefully on the target cells of harmful bacteria. The biological preparation is harmless to animals and humans.
Since July 2023, Eshrifag has been successfully used at the largest livestock complexes in the Russian Federation.
Bacteriophages do not affect the beneficial microflora of the body, acting purposefully on the target cells of harmful bacteria. The biological preparation is harmless to animals and humans.
Since July 2023, Eshrifag has been successfully used at the largest livestock complexes in the Russian Federation.